Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm
Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.
Source: onclive.com